Literature DB >> 32205306

Covid-19: European drugs agency to review safety of ibuprofen.

Michael Day1.   

Abstract

Entities:  

Year:  2020        PMID： 32205306     DOI： 10.1136/bmj.m1168

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  30 in total

1. 

Authors:  Félicie Costantino; Léa Bahier; Luis Coronel Tarancón; Ariane Leboime; François Vidal; Lamouri Bessalah; Maxime Breban; Maria-Antonietta D'Agostino
Journal:  Rev Rhum Ed Fr       Date:  2021-06-05

2.  Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.

Authors:  Ashhar Ali
Journal:  Headache       Date:  2020-05-02       Impact factor: 5.887

3.  Debate on drugs that may aggravate COVID-19.

Authors:  Pedro Giavina-Bianchi; Marcelo Vivolo Aun; Rosana Câmara Agondi; Jorge Kalil
Journal:  J Allergy Clin Immunol Pract       Date:  2020-04-25

4.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Authors:  Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2020-05-29       Impact factor: 19.103

5.  The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.

Authors:  Marco Tuccori; Irma Convertino; Sara Ferraro; Emiliano Cappello; Giulia Valdiserra; Daniele Focosi; Corrado Blandizzi
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.228

6.  Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.

Authors:  Jong-Moon Hwang; Ju-Hyun Kim; Jin-Sung Park; Min Cheol Chang; Donghwi Park
Journal:  Neurol Sci       Date:  2020-07-08       Impact factor: 3.307

Review 7.  How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.

Authors:  Piercarlo Sarzi-Puttini; Daniela Marotto; Marco Antivalle; Fausto Salaffi; Fabiola Atzeni; Giovanni Maconi; Giovanni Monteleone; Giuliano Rizzardini; Spinello Antinori; Massimo Galli; Sandro Ardizzone
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

Review 8.  Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology.

Authors:  Lina María Saldarriaga Rivera; Daniel Fernández Ávila; Wilson Bautista Molano; Daniel Jaramillo Arroyave; Alain Jasaf Bautista Ramírez; Adriana Díaz Maldonado; Jorge Hernán Izquierdo; Edwin Jáuregui; María Constanza Latorre Muñoz; Juan Pablo Restrepo; Juan Sebastián Segura Charry
Journal:  Reumatol Clin (Engl Ed)       Date:  2020-07-28

Review 9.  Etiology and management of liver injury in patients with COVID-19.

Authors:  Rui-Xu Yang; Rui-Dan Zheng; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2020-08-28       Impact factor: 5.742

Review 10.  A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.

Authors:  Yunzhao R Ren; Amit Golding; Alfred Sorbello; Ping Ji; Jianmeng Chen; Bhawana Saluja; Kimberly Witzmann; Vikram Arya; Kellie S Reynolds; Su-Young Choi; Nikolay P Nikolov; Chandrahas Sahajwalla
Journal:  J Clin Pharmacol       Date:  2020-06-24       Impact factor: 2.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.